Home Cart Sign in  
Chemical Structure| 936091-14-4 Chemical Structure| 936091-14-4

Structure of TG101209
CAS No.: 936091-14-4

Chemical Structure| 936091-14-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TG 101209 is a potent and selective JAK2 inhibitor with IC50 of 6 nM, also inhibits Flt3 and RET with IC50 values of 25 nM and 17 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TG101209

CAS No. :936091-14-4
Formula : C26H35N7O2S
M.W : 509.67
SMILES Code : O=S(C1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O
MDL No. :MFCD15528085
InChI Key :JVDOKQYTTYUYDV-UHFFFAOYSA-N
Pubchem ID :16722832

Safety of TG101209

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TG101209

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK3

    JAK3, IC50:169 nM

  • JAK2

    JAK2, IC50:6 nM

  • c-RET

    RET, IC50:17 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Caki-1 6nM 1 day To validate the inhibitory effect of TG-101209 on BUB1B PMC8960981
TEL-JAK2 T-ALL cells 0.125–4 µM 24 hours To evaluate the killing effect of TG101209 on TEL-JAK2 T-ALL cells, the results showed that TG101209 induced dose-dependent apoptosis. PMC3898474
SET-2V617F cells 0.125–2 µM 24 hours To evaluate the killing effect of TG101209 on SET-2V617F cells, the results showed that TG101209 induced dose-dependent apoptosis. PMC3898474
HCC2429 1 μM 24-48 h Inhibited STAT3 phosphorylation and survivin expression, sensitized cells to radiation PMC3104103
CD34+ CML cells 100 nM 3 days To evaluate the growth inhibitory effect of TG101209 on CD34+ CML cells, results showed that TG101209 significantly inhibited the growth of CD34+ CML cells. PMC3601953
H460 3 μM 48 h Inhibited STAT3 phosphorylation and survivin expression, sensitized cells to radiation PMC3104103
Ba/F3-JAK2-V617F cells 10 nM, 15 nM, 20 nM 48 hours Induced apoptosis in Ba/F3-JAK2-V617F cells PMC3743080
K562 cells 0.5 µM 48 hours To evaluate the growth inhibitory effect of TG101209 on K562 cells, results showed that TG101209 significantly inhibited the growth of K562 cells. PMC3601953
U266 5 μM 48 hours preferential killing of CD45+ cells PMC2940994
SET-2V617F cells 0.125–2 µM 48 hours TG101209 induced dose-dependent apoptosis PMC3898474
MM1.S 5 μM 6, 24, 48 hours induction of apoptosis PMC2940994
RPMI 8226 5 μM 6, 24, 48 hours induction of apoptosis PMC2940994
BaF3-EPOR cells 0.6μM TG101209 mildly inhibited colony formation of BaF3-EPOR cells plated on methylcellulose containing a sub-saturating EPO concentration. PMC3221316

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice vhlR200W/R200W knock-in mice Oral gavage 100mg/kg Twice daily for 5 weeks TG101209 treatment reversed the disease phenotype in vhlR200W/R200W knock-in mice, reducing hematocrit (Hct) levels and decreasing the number of megakaryocytes in the spleen. PMC3221316
Mice AE9a leukemia mouse model Oral 100 mg/kg twice daily for two weeks TG101209 effectively reduced tumor burden in AE9a leukemia mice and significantly prolonged survival. PMC3987672
Nude mice Lung cancer xenograft model Oral 100 mg/kg Twice daily for 7 consecutive days Combination of TG101209 and radiation significantly extended tumor growth delay, increased apoptosis, and reduced tumor proliferation and vascular density PMC3104103
Mice NOD/SCID–IL2Rγ-deficient mice Oral 60 mg/kg twice a day for 2 weeks To evaluate the effect of combined treatment with TG101209 and imatinib on the survival of leukemic mice, results showed that the combination treatment significantly prolonged the survival of mice. PMC3601953
Mice TEL-JAK2 T-ALL model Oral 100 mg/kg bid twice daily for 4 days To evaluate the therapeutic effect of TG101209 on TEL-JAK2 T-ALL model mice, the results showed that TG101209 significantly reduced tumor cells in peripheral blood and spleen and prolonged the survival of mice. PMC3898474
Mice TEL-JAK2 T-ALL model Oral 100 mg/kg bid twice daily for 4 days TG101209 significantly reduced tumor cells in peripheral blood and spleen and prolonged the survival of mice PMC3898474

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.81mL

1.96mL

0.98mL

19.62mL

3.92mL

1.96mL

References

 

Historical Records

Categories